AZ licenses NKG2A inhibitor from Innate Pharma

Innate Pharma SA (Euronext:IPH) gained EUR 4.38 (49%) to EUR 13.35 after the MedImmune LLC unit of AstraZeneca plc (LSE:AZN; NYSE:AZN) paid $250 million up front for rights to Innate's IPH 2201 to treat cancer.

The deal gives AZ exclusive, global rights to co-develop and co-commercialize the mAb against killer cell lectin-like receptor subfamily C member 1 ( KLRC1; CD159a; NKG2A) in combination with MEDI4736, its human IgG1 mAb targeting PD-L1. Innate will have the right to co-promote the combination in Europe, where the companies would share profits evenly. ...